作者
Giorgio I Russo, Simone Bier, Jörg Hennenlotter, Gunthild Beger, Lucretia Pavlenco, Jens van de Flierdt, Siegfried Hauch, Moritz Maas, Simon Walz, Steffen Rausch, Jens Bedke, Giuseppe Morgia, Arnulf Stenzl, Tilman Todenhöfer
发表日期
2018/7
期刊
BJU international
卷号
122
期号
1
页码范围
152-159
简介
Objective
To evaluate the presence of circulating tumour cells (CTCs) at different stages of prostate cancer using the AdnaTest® ProstateCancerDetect kit (Qiagen). Moreover, we aimed to assess the expression of transcripts that are specific for cancer stem cells (AdnaTest StemCell) and epithelial–mesenchymal transition (EMT) in CTCs (AdnaTest EMT), as well as additional genes that are known to promote prostate cancer progression.
Patients and Methods
In this prospective study, we included 81 patients who underwent treatment for prostate cancer between 07/2014 and 02/2015, including: Group A, 18 patients (22.2%) with low‐risk clinically localised prostate cancer; Group B, 25 patients (30.9%) with high‐risk clinically localised prostate cancer; Group C, 11 patients (13.6%) with metastatic castration‐sensitive prostate cancer (mCSPC); and Group D, 27 patients (33.3%) with metastatic castration‐resistant …
学术搜索中的文章
GI Russo, S Bier, J Hennenlotter, G Beger, L Pavlenco… - BJU international, 2018